March 15-17, 2016
Boston
2nd Annual
• Develop Successful Combination Strategies
• Validate Novel Pathways
• Identify Clinically Relevant Biomarkers
36 Expert Speakers Including:
Roy Baynes
SVP, Global Clinical
Development
Merck
Pedro Beltran Director Oncology Research
Therapeutic Area
Amgen
Jakob Dupont SVP, CMO OncoMed
Philip Gotwals
Executive Director,
Exploratory
Immuno-Oncology
Novartis
Ed Cha Associate Medical Director
Genentech
Fiona Harding
Senior Principal
Research Scientist
Abbvie
Mary-Lynne Hedley
President and COO
TESARO
Ruslan Novosiadly
Senior Research Advisor,
Biomarkers
Eli Lilly
Dirk Brockstedt
SVP, Research and
Development
Aduro Biotech
Partners:
Researched &
Developed By:
www.immune-checkpoint.com
Tel: +1 212 537 5898 | Email: [email protected]
Immune Checkpoint Inhibitors
@ICI_checkpoint
ICI Boston
March 15-17, 2016
Welcome to ICI Boston
Hear What Previous ICI
Attendees Have To Say:
Optimize The Success Of Your Immuno-Oncology Programs
ICI Boston exists to address the biggest challenges faced in developing
immune modulators.
Excellent meeting.
Great opportunity for
discussions between
academia, small start
ups, large pharma and
regulatory authorities.
The last 12 months have seen an explosion of data, with a renewed
emphasis on inhibitory and agonistic pathways, new disease indications
and combination potential. But, despite the industry making rapid
strides, there is still work to do to replicate the successes of nivolumab
and pembrolizumab.
Working with the likes of BMS, Merck, AstraZeneca and Genentech,
this year’s agenda focuses on novel pathway validation, biomarker
identification and clinical combination strategies.
Gain the latest clinical insights through keynote talks from Roy Baynes
and Michael Giordano as well as previewing innovative work being
carried out by Incyte, Tesaro, GITR Inc. and others.
Accelerate your checkpoint programs by:
•
Hearing about discovery and validation of pathway biologies
beyond PD-1
•
Reviewing immuno-oncology combinations that deliver more
robust and durable responses
•
Learning about novel biomarkers for patient stratification
•
Appreciating the commercial strategy of the current marketed
products
•
Debating clinical strategies to support the rapid generation of
trial data
•
Assessing new preclinical models that effectively recapitulate the
human immune system and improve predictability into the clinic
•
Listening to novel research on the TME, immune ecosystem and
how these influence efficacy
All of the speakers
were very forthcoming
about their developing
pipelines and emerging
therapeutics.
With 33 expert speakers there is a huge amount to learn over the 3 days.
Take a look at the agenda to see what insights will be presented.
What Makes ICI Boston A Must Attend?
In March 2015, 150 experts in the immune checkpoint
field came together and experienced the success of the
first industry-led conference specifically focused on
immune checkpoint modulation.
Building on this success, ICI Boston 2016 represents the
culmination of intensive research into the industry, which
has resulted in the most comprehensive and detailed
agenda of any conference in the area.
ICI Boston is the only conference that will allow you to
rub shoulders with the market leading pharmaceutical
companies. Gain valuable insights into the future of
the field through specifically selected case studies
from some of the most innovative small companies
and pioneering academics in the immune checkpoint
inhibitors space.
Engage with over 200 researchers, all focused on
accelerating the development of the next generation of
checkpoint drugs.
Tel: +1 212 537 5898 Email: [email protected]
www.immune-checkpoint.com Immune Checkpoint Inhibitors
@ICI_checkpoint
ICI Boston
March 15-17, 2016
Speakers
Roy Baynes
SVP, Global Clinical
Development
Merck
Pedro Beltran
Director, Oncology
Research
Therapeutic Area
Amgen
Gary Bembridge
Director,
Scientific Affairs,
Immunology
Abzena
Tehila Ben-Moshe
CEO, VP R&D
cCAM
Biotherapeutics
Dirk Brockstedt
SVP, Research and
Development
Aduro Biotech
Ed Cha Associate Medical
Director Genentech
Greg Dombal
COO
Halloran
Consulting Group
Jakob Dupont SVP, CMO OncoMed
Tara Gangadhar
Assistant Professor,
Abramson Cancer
Center
University of
Pennsylvania
Philip Gotwals
Executive Director,
Exploratory
Immuno-Oncology
Novartis
Fiona Harding
Senior Principal
Research Scientist
Abbvie
Mary-Lynne Hedley
President and COO
TESARO
Henry Hepburne-Scott
Director, Business
Development
Serametrix
Rick Huntress
Senior Manager,
Marketing
The Jackson
Laboratory
Jeff Hutchins
VP, Preclinical
Research
Peregrine
Pharmaceuticals
David Kaufman,
Executive Director,
Translational
Immuno-Oncology
Merck
Francis Kern
Senior Director,
External Scientific
Affairs
Daiichi Sankyo
Holly Koblish
Associate Director
Incyte
Jason Luke
Assistant Professor
University of
Chicago
Walter Newman
Director
Leap Therapeutics
Ruslan Novosiadly
Senior Research
Advisor, Biomarkers
Eli Lilly
Alison O’Mahony
Senior Director,
R&D DiscoverX
Patrick Ott
Clinical Director,
Centre for
Immuno-Oncology
Dana-Farber
Robert Pettit EVP & CSO
Advaxis
Paul Rennert
Founder and
Principal
SugarCone Biotech
Consultants
Matthew Robson VP, Global
Clinical Research,
Immuno-Oncology BMS
Eric Rubin
VP, Global Clinical
Oncology
Merck
Michael Seiler
Associate
Director, Product
Management
Taconic
Philippe Slos
Director, Scientific
Operations
Oncodesign
Isabell Speit
Medical Director EMD Serono
Marc Theoret Lead Medical Officer
FDA
Chris Turner
VP, Clinical Science
Celldex
James Vasselli
Vice President,
Clinical Research
Macrogenics
Jennifer Wargo
Associate Professor
MD Anderson Cancer
Centre
Andrew Ferguson
Clinical Scientist
TESARO
Eustache
Paramithiotis VP, Biomarker
Discovery &
Diagnostics Caprion
This conference was of outstanding value. First class
presentations, great opportunity for networking and
perfect logistics!
AstraZeneca, ICI Europe Attendee
Tel: +1 212 537 5898 Email: [email protected]
www.immune-checkpoint.com Immune Checkpoint Inhibitors
@ICI_checkpoint
ICI Boston
March 15-17, 2016
Conference Agenda, Day One – Wednesday March 16
8.15
Mary-Lynne Hedley, President
and COO, TESARO
Chair’s Opening Remarks
Capitalize on Future ICI Opportunities
8.30
Anti-PD-1 Antibody Holds the Promise of Being a Broad Spectrum
Antineoplastic Therapy
•Investigating adaptive phase 1 and parsimonious screening phase 2 studies that have
accelerated development
•Analyzing the breadth and depth of the PD-1 antibody addressable cancers
•Selecting the appropriate patients for monotherapy and for the exploration of novel
approaches including combinations
Roy Baynes, SVP, Global Clinical
Development, Merck
9.00
Talk Title and Details to be Confirmed
Marc Theoret, Lead Medical
Officer, FDA
9.30
Speed Networking & Morning Refreshments
Preclinical Stream
Clinical Stream
Validate Novel Immuno-Modulatory Checkpoints
Enhance Combination Strategies to Maximize Efficacy
11.00 Treating Cancer by Targeted Activation of the
Immune System
11.00 Critically Evaluate The Use of Multiple
Checkpoint Inhibitors in Combination
11.30 Small Molecule Inhibition of Tumor Immune
Suppression: IDO1 and Beyond
11.30 Enhancing the Power of Checkpoint Inhibition
by Simultaneously Blocking Upstream and
Downstream Targets: The Role of Phosphatidylserine
(PS), a Novel, Global Immune Checkpoint
• Discussing the role of checkpoint inhibitors in the context of
a broader immuno-oncology strategy
• Outlining the status of the Novartis checkpoint pipeline
• Reviewing approaches to the discovery of novel CPIs
Phil Gotwals, Executive Director, Immuno-Oncology, Novartis
• Selective IDO1 inhibition modulates the immune
microenvironment and impacts tumor growth in
preclinical models
• Combinations of IDO1 inhibition and checkpoint blockade
allow for increased efficacy in preclinical models and
disease control in cancer patients
• Selective JAK and PI3Kδ inhibition could be alternative
strategies to enhance immune responses to tumors and are
worthy of clinical study
Holly Koblish, Associate Director, Pharmacology, Incyte
12.00 Tipping the Balance: the Potential of TIM-3
and LAG-3 Inhibition to Augment Immunotherapy
• Inhibitory vs stimulatory effects of TIM-3 and LAG-3 on
innate and adaptive immune cells
• Expression of TIM-3 and LAG-3 in various tumor types
• Preclinical support for TIM-3 and LAG-3 expression in
murine and ex vivo tumor models
• Do you always need PD-1/L1 blockade?
Andrew Ferguson, Clinical Scientist, TESARO
• Build on the lessons learned from combining nivolumab and
ipilimumab for the treatment of melanoma
• Examine multiple variables contributing to successful
combination strategy, including dosing and treatment timing
• Use these insights to improve combination trial design
Patrick Ott, Clinical Director, Centre for Immuno-Oncology,
Dana-Farber
• Inhibiting PS using Bavituximab, a novel PS-signaling pathway
inhibitor, blocks the immunosuppressive signal within the
tumor microenvironment
• Assessing impact of immune stimulation through
Fcγ-receptor interaction on immune modulating cells
• Effects on multiple other immune effector cells will
be presented
Jeff Hutchins, VP, Preclinical Research, Peregrine
Pharmaceuticals
12.00 Releasing the Brake: Enhancing
Immunotherapy Through Rational Combinations
with Checkpoint Inhibitors
• Understand the key principals governing logical immunooncology combination strategies
• Lessons learnt from combining the novel target B7-H3 with
ipilimumab and pembrolizumab
• Insights into the most promising future
combination strategies
James Vasselli, Vice President, Clinical Research,
Macrogenics
12.30 Lunch & Networking
Tel: +1 212 537 5898 Email: [email protected]
www.immune-checkpoint.com Immune Checkpoint Inhibitors
@ICI_checkpoint
ICI Boston
March 15-17, 2016
1.30 Laying the Foundation for Future ImmunoOncology Combinations with Therapeutic Vaccines:
Lm Vaccines, Checkpoint Inhibition, Co-Stimulatory
Agonism, and the Tumor Microenvironment
1.30 Overcoming Toxicities Associated with Novel
Checkpoint Inhibitor Immunotherapy
2.00 Preclinical Pharmacology of Murine and
Human Anti-GITR Antibodies
2.00 Discovery and Validation of the Next
Generation of Immune Checkpoint Inhibitors
2.30 Extended Q & A
2.30 Next-Generation Biomarkers for the Era of
Combination Cancer Immunotherapy
• Provide an overview of Lm vectors, the immunologic macroenvironment, and tumor microenvironment
• Discuss the synergistic effects of combining Lm based
immunotherapies with checkpoint inhibitors and agonists
• Highlight the evolution of therapeutic vaccination
immunotherapy— Tumor driver targets, vaccine platforms,
and personalized neoepitope vaccination
Robert Pettit, EVP & CSO, Advaxis
• Preclinical data with anti-GITR mAbs demonstrate unique
immune activation and potential as oncologic therapies
• TRX 518 is a humanized anti-human GITR mAb that is
currently in the clinic. Based on the data to date, it will be
evaluated in further single and combination therapy studies
Walter Newman, Director, Leap Therapeutics
• Review toxicity profiles of checkpoint blockade and dual
checkpoint blockade
• Monitoring and management of checkpoint
blockade-associated toxicities
• Clinical perspectives on the challenges of immune
toxicity management
• Differences in AE assessment and management during drug
development in phase I/II versus phase III and implications/
expectations for assessing drug tolerability
Tara Gangadhar, Assistant Professor, University of Pennsylvania
• Investigate strategies to validate novel checkpoint pathways
and the potential of novel targets and combination with
active immunization
• Impact on the future of the immune checkpoint inhibitor field
Dirk Brockstedt, SVP, Research and Development,
Aduro Biotech
• Biomarker and companion diagnostic development in the
pembrolizumab program
• Translational research and biomarker approaches to address
combination approaches in immuno-oncology
David Kaufman, Executive Director, Translational ImmunoOncology, Merck
3.00
Afternoon Refreshments & Networking
Harness Clinically Relevant Tumor Models
3.30
Precision Research Models of Human Immune System and Metabolic
Function: Applications in Oncology Drug Discovery
•Current state of immune system engraftment models
•The next generation huNOG-EXL which extends the mechanistic functionality of
current systems
Michael Seiler, Associate
Director, Product Management,
Taconic
• Recent advances in immuno-oncology applications with immune system engrafted mice
4.00
Addressing Challenges Associated with Modeling Immuno-Oncology Therapies in Immunocompetent Animal Models
• Considerations for selecting surrogate mAbs for immuno-oncology studies
Fiona Harding, Senior Principal
Research Scientist, Abbvie
• Immunocompetent murine tumor models: Selection of models and interpretation of results
4.30
Patient Derived Xenografts In Humanized (CD34+) NSG Mice – Immuno-Oncology Efficacy Testing
• Evaluate experiments engrafting PDX tumors into humanized (CD34+) NSG mice
• Critically review the treatment of these tumor bearing mice with both traditional SOC
drugs & checkpoint inhibitors
Rick Huntress, Senior Manager,
Marketing, The Jackson
Laboratory
• Overview of the differences in tumor growth rate, SOC response & immune modulation
as a component of preclinical drug efficacy testing will be discussed
5.00
Enabling Cancer Immunotherapy From Discovery to Combinations
Key discussion points:
• How do I identify a functionally active lead molecule?
• How can I determine the efficacy of my drug in a human tumor microenvironment?
• Is my drug safe for the patient outside the cancer context?
• Are my drug combinations active, safe and different?
Tel: +1 212 537 5898 Email: [email protected]
www.immune-checkpoint.com Immune Checkpoint Inhibitors
@ICI_checkpoint
Alison O’Mahony, Senior
Director, R&D, DiscoverX
ICI Boston
March 15-17, 2016
Conference Agenda, Day Two – Thursday March 17
8.45
Tehila Ben-Moshe,
CEO, VP R&D, cCAM
Biotherapeutics
Chair’s Opening Remarks
Improve Clinical Outcomes With Checkpoint Modulators
9.00
Jumping the Next Hurdle: Overcoming Challenges Inhibiting the Efficacy of
Approved PD-1 and CTLA-4 Inhibitors
• Assessing strategies to extend therapeutic benefits to reach a larger proportion of patients
•Understanding the optimum timing of ICI administration in relapsing patients
•Discover the effects of PD-1 blockade on the tumour microenvironment
•Assessing the durability of response to PD-1 and CTLA-4 treatment
9.30
Mechanisms of Action of Talimogene Laherparepvec and Potential for Combination
with Checkpoint Inhibitors
•Talimogene laherparepvec is the first injectable, modified oncolytic herpes simplex virus type-1
(HSV-1)-based immunotherapy approved in the US
•Talimogene laherparepvec is hypothesized to be efficacious by at least two complimentary
mechanisms of action: a) direct oncolysis and b) systemic anti-tumor adaptive immune response
•Logical immunotherapy combinations involving talimogene laherparepvec and checkpoint
inhibitors are being studied in preclinical animal models and patients with metastatic melanoma
Matthew Robson,
VP Global Clinical
Research
Immuno-Oncology,
Bristol-Myers
Squibb
Pedro Beltran,
Director, Oncology
Research
Therapeutic Area,
Amgen
10.00 Morning Refreshments & Networking
Preclinical Stream
Clinical Stream
Advance Understanding of the Immune Ecosystem
Investigate Clinical Strategies to Monitor Immune
Responses and Adverse Events
10.30 Advances in In Vitro PBMC Assays to Measure
Functionality of ICIs Preclinically
10.30 The Emergence of icScoreTM as a Novel
Immune-Based Approach for Monitoring Cancer
Patients
• More details to be disclosed shortly
Gary Bembridge, Director, Scientific Affairs,
Immunology, Abzena
• Cancer immunotherapies offer great promise but some
patients fail to respond
• Immune-based biomarker assays can help predict clinical
response to this emerging drug class
• Serametrix has developed icScoreTM, an immune monitoring
system designed for cancer patients
Henry Hepburne-Scott, Director, Business
Development, Serametrix
11.00 Utilizing the T Cell-Inflamed Tumor
Microenvironment to Guide Immunotherapy
Development for Melanoma and Human Solid Tumors
11.00 Examining the Safety Profile of Checkpoint
Inhibitors: Current Status and Lessons Learned
11.30 Biomarker Discovery In Immuno-Oncology:
From The Bench To The Bedside And Back
11.30 Direct Identification of Neo-Epitopes for Cancer
Vaccines and Adoptive T-Cell Therapies
• Discuss the clinical implications of anti-CTLA-4 and antiPD-1 antibodies in sequence and combination for melanoma
• Utilize the T cell-inflamed tumor microenvironment
as a more encompassing and clinically useful model for
immunotherapy biomarker development compared with PD-L1
• Develop rational molecular and immunological
combinatorial strategies for melanoma and other solid
tumors based on improved understanding of the TME
Jason Luke, Assistant Professor, University of Chicago
• Biomarker discovery paradigm in immuno-oncology – a shift
from hypothesis-testing to hypothesis-generation
• High-throughput, high-content molecular and immune
profiling enables comprehensive biomarker evaluation
• Interrogation of mechanistic biomarkers provides insight into
rational combinations in immuno-oncology
Ruslan Novosiadly, Senior Research Advisor, Cancer Biology
Biomarkers, Eli Lilly
• Administration of checkpoint inhibitors may result in adverse
events that are caused by the intrinsic mode of action of
these drugs and are so called immune-related adverse events
• Immune-related adverse events patterns have been
extensively described
• Their management (early detection and early management)
has improved and has contributed to broaden their use as a
monotherapy or in combination
Isabell Speit, Medical Director, EMD Serono
• Direct detection of peptides presented by MHC is the most
physiologically relevant way to identify both modified and
non-modified neo-epitopes associated with cancer
• Naturally presented peptides were characterized in a pilot
study of surgically resected renal cell carcinoma
• Characteristics of overall peptide presentation as well as
specific examples of cancer associated peptides
will be presented
Eustache Paramithiotis, VP, Biomarker Discovery &
Diagnostics, Caprion
Tel: +1 212 537 5898 Email: [email protected]
www.immune-checkpoint.com Immune Checkpoint Inhibitors
@ICI_checkpoint
ICI Boston
March 15-17, 2016
12.00 Lunch & Networking
Identify Translational Biomarkers to Stratify
Patient Populations
Investigate Clinical Strategies to Monitor Immune
Responses and Adverse Events
1.00 Predictive Biomarkers for Pembrolizumab
1.00 Deconstructing the Atezolizumab Success
Story: Gain Valuable Insights
From the Trailblazing PD-L1 Inhibitor
• Clinical utility of PD-L1 immunohistochemistry in identifying
responders to pembrolizumab
• Beyond PD-L1 immunohistochemistry – potential of RNAand DNA-based assays to identify responders
to pembrolizumab
Eric Rubin, VP, Global Clinical Oncology, Merck
1.30 Understanding the Dynamics and
Heterogeneity of Responses to Immune Checkpoint
Blockade: Opportunities to Enhance Responses
Through Translational Research
• Significant advances have been made in cancer therapy via
the use of immune checkpoint blockade, but responses are
heterogeneous and are not always durable
• Current predictive biomarkers in pre-treatment tumor
samples are not robust, and better biomarkers in tumor (and
in blood) are critically needed
• Molecular and immune profiling in longitudinal samples from
patients on immune checkpoint blockade to identify putative
biomarkers that are highly predictive of response
• Identifying putative mechanisms of therapeutic resistance
and novel means to enhance response to therapy
Jennifer Wargo, Associate Professor, MD Anderson
Cancer Center
2.00 Evaluation of Immunomodulatory Agents in
Syngeneic Models and Immune Cell Phenotyping
of Humanized Mouse Models Carrying PatientDerived Tumors
• Demonstrating a key panel of syngeneic models with
response data to immune checkpoint inhibitor antibodies as
monotherapies and combinations, allowing informed design
and strategy for combination studies
• Characterization and sequencing data in the syngeneic
models and functionality assays can be leveraged in proofof-concept studies to investigate the mechanism of drughost immune system interactions
• Immunophenotyping humanized PDX models serves
to identify the presence and changes in circulating and
central human lymphoid and myeloid cell populations,
enabling further evaluation of compounds targeting Tregs or
interfering with CD8/CD4 populations
Philippe Slos, Director, Scientific Operations, Oncodesign
2.30
• Discover the potential of atezolizumab monotherapy and
combination therapy as a front-line treatment
• PD-L1 expression as a predictive biomarker: Insight into
responder populations in atezolizumab trials
• Understand the rationale governing atezolizumab
combination strategy
Ed Cha, Associate Medical Director, Genentech
1.30 Inhibition of the Novel Immune Checkpoint
CEACAM1 Enhances Anti-Tumor Immunological
Activity
• CEACAM1 is expressed by T and NK cells upon activation,
and expression is seen across multiple tumor types
independently of PD-L1 expression
• Homophilic CEACAM1 interactions induce co-inhibitory
signals to lymphocytes
• The first in class humanized anti-CEACAM1 mAb CM24 (MK6018) inhibits the immunosuppressive effect of CEACAM1,
leading to enhanced cancel cell killing by T and NK cells
Tehila Ben-Moshe, CEO, VP R&D, cCAM Biotherapeutics
2.00 Augmenting the Potency of Checkpoint
Blockade by Combinations of Multiple Immune
Modulators at Selected Steps in Immune Activation
• Mechanism of action of varlilumab, a fully human
monoclonal agonist antibody that targets CD27, to enhance
immune activation
• Using the agonist antibody varlilumab in combination with
checkpoint inhibitors to augment anti-tumor activity
• Targeting tumor-specific protein antigens to the DEC-205
receptor on dendritic cells
Chris Turner, VP, Clinical Science, Celldex
Afternoon Refreshments & Networking
Navigate the Commercial Landscape to Ensure Future Success
3.00
Remaining Competitive in a Rapidly Evolving Field: Strategies to Establish
and Reinforce Market Share
•Learn from case studies detailing mutually beneficial partnerships in the ICI space
•Explore methods of successfully adapting to an expanding field
3.30
Cross-Industry Perspectives on the Future of ICIs
4.15
Chair’s Closing Remarks
• How can past challenges be interrogated to develop successful future strategies?
• What are the most immediate challenges that need to be prioritized?
• What does the next 5-10 years hold for the field?
Tel: +1 212 537 5898 Email: [email protected]
www.immune-checkpoint.com Immune Checkpoint Inhibitors
@ICI_checkpoint
Francis Kern, Senior Director,
External Scientific Affairs, Daiichi
Sankyo
Panellists:
Ed Cha, Associate Medical
Director, Genentech
Patrick Ott
Dana-Farber
ICI Boston
March 15-17, 2016
Workshops - Tuesday March 15
Pre Conference Workshop A
8.30am-11.30am
Review of the Immune Checkpoint Inhibitors Landscape
Back by
popular
!
demand
Building on the success of this workshop at last year’s conference, this interactive discussion will
provide a valuable overview of the current state of the field and evaluate some of the most exciting
future industry trends in immunotherapy, with a particular focus on combinatorial therapies.
In such a rapidly evolving field, the opportunity to learn about and discuss current and future
strategies make this workshop a must-attend.
Attendees will learn:
•
From a comprehensive overview of the most innovative case studies in the field
•
Lessons from the clinical development of immune checkpoint inhibitors
•
What the next five years will hold for this rapidly evolving space
Pre Conference Workshop B
Workshop leader
Paul Rennert
Founder and Principal
SugarCone Biotech
Consultants
12.00pm-3.00pm
Focus on Biomarkers: Identifying Companion Diagnostics to Predict the
Relative Success Rate of Immune Checkpoint Blockade
The development and utility of clinical biomarkers has emerged as one of the most pressing
challenges facing the immune checkpoint inhibitor field. Through this workshop, gain an in-depth
understanding of this crucial aspect and learn about the current progress and future of biomarker
development in this space. Case studies will focus on the advantages and disadvantages of various
biomarker strategies, with the aim of identifying the most promising biomarker programs in
development. Additional factors affecting the sensitivity to checkpoint blockade therapy will be
discussed, for example an insight into how the mutational and neoantigen landscape of the tumor
can determine sensitivity to PD-1 blockade.
Attendees will learn:
•
Evaluate the true value of PD-L1 as a relevant biomarker
•
Analyse key factors determining sensitivity to immune checkpoint modulation
•
Investigate the clinical relevance of novel biomarkers across tumor types
Pre Conference Workshop C
Workshop leader
Jakob Dupont SVP, CMO
OncoMed
3.30pm-6.30pm
Overcome the Regulatory Challenges Encountered in the Development of the
Next Generation of Immune Checkpoint Inhibitors
One of the most critical clinical considerations in the development of checkpoint inhibitors is
identifying appropriate measures of clinical effect. The tools we use to measure success on a
patient-by-patient level are essential for charting and staying a regulatory course.
This workshop will assess the relevance of traditional endpoints in measuring the clinical success of
compounds, and discuss how existing regulatory criteria need to adapt to accommodate the specific
challenges involved in the clinical development of immune checkpoint inhibitors. Case studies will
outline relevant regulatory cases in the wider immuno-oncology field and assess the lessons that can
be taken from these examples.
Attendees will learn:
•
The relevance of some traditional endpoints in checkpoint inhibitor trials
•
Insight from a regulatory perspective on the immune checkpoint inhibitors field
•
How the regulatory landscape of the area may adapt in response to new innovations
Tel: +1 212 537 5898 Email: [email protected]
www.immune-checkpoint.com Immune Checkpoint Inhibitors
@ICI_checkpoint
Workshop leader
Greg Dombal
COO
Halloran Consulting
Group
ICI Boston
March 15-17, 2016
Networking
At ICI Boston
Speed Networking
Run like speed dating, this structured networking session
will facilitate quick introductions with the majority of
attendees. Use this time wisely to meet others in the
immuno-oncology field and identify those you want to
spend more time with.
Interactive Panel Discussions
Take part in interactive discussion sessions focused around
specific, high priority issues. Query the experiences and
observations of our senior level speaker panel. Uncover
new ideas and insights to fast track your own research.
Perfect organization. Program
well planned with sufficient time
for networking
BMS
You’ll Meet People From...
6%
Pharma
5%
In between the formal presentations the networking carries
on. Use the multiple refreshment and lunch breaks to
continue your discussions in an informal
relaxed atmosphere.
15%
Platform Technology
27%
8%
Structured Networking Breaks
Biotech
CRO
INDUSTRY
BREAKDOWN
Academics
Dx
Others
20%
19%
C-Level
18%
20%
23%
SENIORITY
BREAKDOWN
17%
VP
Director
22%
Manager
Scientist
23%
*Based on 2015 attendance
Companies Which Attend ICI Include:
Quick Fire Figures
87 companies
attended last year
of
11 hours
networking
User
74% End
Audience
Tel: +1 212 537 5898 Email: [email protected]
www.immune-checkpoint.com Immune Checkpoint Inhibitors
@ICI_checkpoint
ICI Boston
March 15-17, 2016
Sponsors
Program Partners
Partners
ABR| HEALTHCO.
Exhibitors
Partner with Us
Contact
Jason Williams
Commercial Director
Tel: +44 (0)203 141 8711
Email: [email protected]
Tel: +1 212 537 5898 Email: [email protected]
www.immune-checkpoint.com Immune Checkpoint Inhibitors
@ICI_checkpoint
ICI Boston
March 15-17, 2016
Venue
Venue: Just a stone’s throw away from the Commons, this
boutique hotel takes inspiration from the city’s rich history
while revelling in the unpredictable. Each space at Revere
Hotel complements the next, allowing you to create your own
unique and original Boston experience. Explore a completely
new side of the city at this luxury hotel in Boston.
Very well organised conference and very
focused on topics that matter. Top speakers. The
best conference in the field in my opinion.
Glenmark
Hotel name:
Revere Hotel Boston Common
200 Stuart Street
Boston MA 02116
United States
www.reverehotel.com
Accommodation: Overnight accommodation and travel
are not included in the registration fee.
Prices & Discounts
Register and pay before January 29th 2016
Standard
Pricing
Platinum:
Conference + 3 workshops
$4296 (save $500)
$4496 (save $300)
Gold:
Conference + 2 Workshop
$3687 (save $400)
$3897 (save $200)
Silver:
Conference + 1 workshop
$3098 (save $300)
$3298 (save $100)
Bronze:
Conference only $2499 (save $200)
$2699
$699
$699
Package Prices
Workshops (Each)
Not-for-profit rates are available online for government, academic and charitable organisations.
Team Discounts*
3+ Delegates: 10% Discount
4+ Delegates: 15% Discount
5+ Delegates: 20% Discount
*Please note: Team discounts are only valid when three or more delegates from one company book and pay
at the same time. ‘Early Bird’ discounts require payment at the time of registration (or prior to the cut-off
date) to secure the applicable discount. All advertised discounts cannot be combined with any other offer.
When you’ve made your selections
Secure Your Place
Attend ICI Boston To:
1
Develop Successful Combination Strategies
You can register your place quickly
and easily online. Visit:
2
Validate Novel Pathways
www.immune-checkpoint.com/take-part/register/
Identify Clinically Relevant Biomarkers
If you require any further information on the event, or would like
us to assist you in making your booking, please contact Hanson
Wade via the contact details below.
3
Contact us:
TERMS & CONDITIONS
Changes to Conference & Agenda: Hanson Wade reserves the right to
postpone or cancel an event, to change the location or alter the advertised
speakers. Hanson Wade is not responsible for any loss or damage or costs
incurred as a result of substitution, alteration, postponement or cancellation
of an event for any reason and including causes beyond its control including
without limitation, acts of God, natural disasters, sabotage, accident, trade or
industrial disputes, terrorism or hostilities.
Data Protection: The personal information shown and/or provided by you will
be held in a database. It may be used to keep you up to date with developments
in your industry. Sometimes your details may be obtained or made available to
third parties for marketing purposes. If you do not wish your details to be used
for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6
Honduras Street, London EC1Y 0TH
Tel: +1 212 537 5898 Email: [email protected]
www.immune-checkpoint.com Immune Checkpoint Inhibitors
@ICI_checkpoint
Code: 6190
Full payment is due on registration. Cancellation and Substitution Policy:
Cancellations must be received in writing. If the cancellation is received more
than 14 days before the conference attendees will receive a full credit to a
future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution
from the same organization can be made at any time.